港股異動 | 蘋果概念股走低 iPhone在華單週銷量跌27%
格隆匯11月3日丨連續反彈2日的蘋果概念股再度下跌,高偉電子跌5.67%,舜宇光學跌4%,比亞迪電子跌3.5%,瑞聲科技、丘鈦科技均跌2%。近日,國外卻發佈了有關iPhone銷量的報告,報告中指出iPhone在華上一週的銷量暴跌了27%。與此同時,報告還強調,這已經是iPhone在中國銷量急劇下降的第三週。分析師李裕生表示,雖然iPhone 14系列提前一週發佈也對銷量同比下跌有所影響,但銷量負面趨勢仍無法忽視,而且比其他安卓廠商機型銷量下跌得更爲糟糕(iPhone 14全系列在華渠道報價已低於官網首發價)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.